

# Genital Herpes Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/G3D65F9D69BBEN.html>

Date: May 2024

Pages: 132

Price: US\$ 6,499.00 (Single User License)

ID: G3D65F9D69BBEN

## Abstracts

The 7 major genital herpes markets are expected to exhibit a CAGR of 3.49% during 2024-2034.

The genital herpes market has been comprehensively analyzed in IMARC's new report titled "Genital Herpes Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Genital herpes is a common sexually transmitted illness that is caused by the herpes simplex virus (HSV). It primarily affects the genital and anal regions of the body, but it can also occur on the skin around the buttocks and thighs. The primary mode of viral spread is through sexual activity with an infected individual or direct skin-to-skin contact with a diseased area. Some common symptoms of this ailment include itching, tingling, or burning sensations, painful sores or blisters in the genital or anal region, fever, headache, muscle aches, swollen lymph nodes, etc. The diagnosis of the illness is mainly based on the patient's medical history, clinical features, and physical examination. Additionally, blood workups are recommended to detect the presence of antibodies against HSV, indicating a past or current infection even when no active symptoms are present. The healthcare provider will perform a polymerase chain reaction (PCR) test to determine the genetic material (DNA) of the herpes virus in the patient's sample. Furthermore, a viral culture screening is also required to confirm the diagnosis and identify the subtypes of the virus.

The increasing prevalence of unprotected sexual activities, including vaginal, anal, or oral sex, that can enhance the likelihood of viral transmission among individuals is primarily driving the genital herpes market. In addition to this, the rising cases of weakened immune systems, which impair the body's ability to recognize and attack the pathogen, allowing it to replicate and cause active infections, are creating a positive

outlook for the market. Moreover, the widespread adoption of antiviral drugs, like acyclovir, valacyclovir, famciclovir, etc., to shorten the duration of outbreaks, alleviate symptoms, and reduce the risk of viral transmission is further bolstering the market growth. Apart from this, the inflating application of topical analgesics, since they can be applied directly to the sores or blisters, thereby accelerating the healing mechanism and improving overall well-being, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of nucleoside reverse transcriptase inhibitors, which prevent viral replication by interfering with the DNA synthesis process, is expected to drive the genital herpes market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the genital herpes market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for genital herpes and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the genital herpes market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

## Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the genital herpes market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the genital herpes market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current genital herpes marketed drugs and late-stage pipeline drugs.

## In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

## Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

## Key Questions Answered in this Report:

Market Insights

How has the genital herpes market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they

expected to perform till 2034?

What was the country-wise size of the genital herpes market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the genital herpes market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of genital herpes across the seven major markets?

What is the number of prevalent cases (2018-2034) of genital herpes by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of genital herpes by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with genital herpes across the seven major markets?

What is the size of the genital herpes patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of genital herpes?

What will be the growth rate of patients across the seven major markets?

### Genital Herpes: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for genital herpes drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the genital herpes market?

What are the key regulatory events related to the genital herpes market?

What is the structure of clinical trial landscape by status related to the genital herpes market?

What is the structure of clinical trial landscape by phase related to the genital herpes market?

What is the structure of clinical trial landscape by route of administration related to the genital herpes market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 GENITAL HERPES - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 GENITAL HERPES - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 GENITAL HERPES - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 GENITAL HERPES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 GENITAL HERPES - UNMET NEEDS**

## **10 GENITAL HERPES - KEY ENDPOINTS OF TREATMENT**

## **11 GENITAL HERPES - MARKETED PRODUCTS**

- 11.1 List of Genital Herpes Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Zovirax (Acyclovir) - GlaxoSmithKline
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets
  - 11.1.2 Famvir (Famciclovir) - Novartis
    - 11.1.2.1 Drug Overview



- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Valtrex (Valaciclovir) - GlaxoSmithKline
  - 11.1.3.1 Drug Overview
  - 11.1.3.2 Mechanism of Action
  - 11.1.3.3 Regulatory Status
  - 11.1.3.4 Clinical Trial Results
  - 11.1.3.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## **12 GENITAL HERPES - PIPELINE DRUGS**

### 12.1 List of Genital Herpes Pipeline Drugs Across the Top 7 Markets

- 12.1.1 BNT163 - BioNTech
  - 12.1.1.1 Drug Overview
  - 12.1.1.2 Mechanism of Action
  - 12.1.1.3 Clinical Trial Results
  - 12.1.1.4 Safety and Efficacy
  - 12.1.1.5 Regulatory Status
- 12.1.2 HDIT101 - Heidelberg ImmunoTherapeutics
  - 12.1.2.1 Drug Overview
  - 12.1.2.2 Mechanism of Action
  - 12.1.2.3 Clinical Trial Results
  - 12.1.2.4 Safety and Efficacy
  - 12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. GENITAL HERPES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. GENITAL HERPES – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration

## 14.4 Key Regulatory Events

## **15 GENITAL HERPES - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Genital Herpes - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Genital Herpes - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

#### 15.3.1 Genital Herpes - Market Size

##### 15.3.1.1 Market Size (2018-2023)

##### 15.3.1.2 Market Forecast (2024-2034)

#### 15.3.2 Genital Herpes - Market Size by Therapies

##### 15.3.2.1 Market Size by Therapies (2018-2023)

##### 15.3.2.2 Market Forecast by Therapies (2024-2034)

#### 15.3.3 Genital Herpes - Access and Reimbursement Overview

### 15.4 Market Scenario - Germany

#### 15.4.1 Genital Herpes - Market Size

##### 15.4.1.1 Market Size (2018-2023)

##### 15.4.1.2 Market Forecast (2024-2034)

#### 15.4.2 Genital Herpes - Market Size by Therapies

##### 15.4.2.1 Market Size by Therapies (2018-2023)

##### 15.4.2.2 Market Forecast by Therapies (2024-2034)

#### 15.4.3 Genital Herpes - Access and Reimbursement Overview

### 15.5 Market Scenario - France

#### 15.5.1 Genital Herpes - Market Size

##### 15.5.1.1 Market Size (2018-2023)

##### 15.5.1.2 Market Forecast (2024-2034)

#### 15.5.2 Genital Herpes - Market Size by Therapies

##### 15.5.2.1 Market Size by Therapies (2018-2023)

##### 15.5.2.2 Market Forecast by Therapies (2024-2034)

#### 15.5.3 Genital Herpes - Access and Reimbursement Overview

### 15.6 Market Scenario - United Kingdom

#### 15.6.1 Genital Herpes - Market Size

##### 15.6.1.1 Market Size (2018-2023)

- 15.6.1.2 Market Forecast (2024-2034)
- 15.6.2 Genital Herpes - Market Size by Therapies
  - 15.6.2.1 Market Size by Therapies (2018-2023)
  - 15.6.2.2 Market Forecast by Therapies (2024-2034)
- 15.6.3 Genital Herpes - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Genital Herpes - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Genital Herpes - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Genital Herpes - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Genital Herpes - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Genital Herpes - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Genital Herpes - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Genital Herpes - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Genital Herpes - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Genital Herpes - Access and Reimbursement Overview

## **16 GENITAL HERPES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 GENITAL HERPES MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 GENITAL HERPES MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Genital Herpes Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/G3D65F9D69BBEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3D65F9D69BBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

